Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 46

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 46
---
apeutic program for neuroblastoma and potentially other indications with DiamiR’s technology; •the potential enhanced ability to raise capital utilizing a broader potential product portfolio; •Company’s projected cash position and the difficulties the Company has encountered in raising sufficient capital on a stand -alonebasis; •the risks of continuing to operate Company on a stand -alonebasis, including uncertainty regarding Company’s product development and the need to raise significant additional financing for future clinical and commercial development; •the low valuation of the Company on a stand -alonebasis currently evidenced by the trading price of Company’s Class A ordinary shares; •the strategic alternatives to the Merger, including the discussions that Company’s management and advisors previously conducted with other potential partners, and the lack of any viable alternatives; and •the view of Company that the consideration is fair, from a financial point of view, to the holders of Company’s Class A ordinary shares. The Company’s board of directors believed that, as a result of arm’s length negotiations with DiamiR, Company and its management team negotiated the most favorable implied value and equity split for its stockholders that DiamiR was willing to agree to, and that the terms of the Merger Agreement include the most favorable terms to Company in the aggregate to which DiamiR was willing to agree. Immediately prior to signing the Merger Agreement, Company’s stock price was $0.94 per share, as quoted on Nasdaq on July 11, 2025. Aptorum and DiamiR agreed that DiamiR would have a valuation of $18.7million at the time of closing of the Merger. The Company board of directors also believed, after a thorough review of strategic alternatives and discussions with Company’s senior management and legal counsel, that the Merger is more favorable to its stockholders than the potential value that might have resulted from other strategic options available to Company, which would likely be a delisting of the Company’s Class A ordinary shares from Nasdaq if the Merger is not consummated. 6 After giving consideration to these and other factors, the Company board of directors approved the Merger, which the Company board of directors believes better positions Company for long -termsuccess. DiamiR’s Reasons for the Merger DiamiR’s decision to proceed with the strategic combination with Aptorum Group, is based on the following considerations: •DiamiR Biosciences has experience in microRNA (miRNA) biomarker discovery and validation and experience in miRNA testing, characterization and quantification; D